CHMP recommends EU approval of Roche’s Susvimo for nAMD treatment
The CHMP has recommended the approval of Susvimo, a continuous delivery treatment for nAMD, based on clinical trial data.
Company
Roche
Asset
Signal assessment
Signal strength
critical
Confidence level
high
Why it matters
The CHMP's recommendation for Susvimo marks a significant advancement in the treatment of nAMD, potentially transforming patient care and Roche's market position. This approval could lead to increased patient adherence and reduced treatment burden, making it a pivotal moment for Roche in ophthalmology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the final decision from the European Commission and subsequent market uptake of Susvimo in the EU.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.